Ascentawits

About Ascentawits

Ascentawits Pharmaceuticals, Ltd., known as Shenzhen Ascentawits Pharmaceutical Technology Co., Ltd. in China, is a clinical-stage biopharmaceutical company established in Shenzhen in 2014. The company was co-founded by Dr. Jianxin Duan and Ms. Yanbin Xie. Dr. Duan, who serves as Chairman and CEO, brings over two decades of experience in small-molecule drug research and development, holding a Ph.D. in Chemistry from the University of Florida. His extensive background in anticancer drug research includes leading multiple projects into clinical trials during his time at Threshold Pharmaceuticals in the US. Ms. Xie is a recognized figure in China's clinical research sector, having founded one of the country's first contract research organizations (CROs).

The firm's core business revolves around the discovery and development of innovative small-molecule drug conjugates (SMDCs), a targeted approach for cancer therapy. This technology aims to create "magic bullets" that selectively kill tumor cells while minimizing harm to healthy cells, thereby reducing side effects compared to traditional chemotherapy. The company's strategy is to utilize the specific tumor microenvironment to design and screen novel anti-tumor prodrugs. Ascentawits operates in the oncology market, focusing on developing treatments for various cancers. Its business model is centered on in-house research and development, progressing proprietary drug candidates through the clinical trial pipeline, and potentially out-licensing or collaborating with other pharmaceutical companies to bring products to market.

Ascentawits has built a pipeline of proprietary drug candidates with global intellectual property rights. A key asset is AST-3424, a first-in-class small molecule new drug that targets the AKR1C3 enzyme, which is overexpressed in as many as 15 types of solid and hematological tumors, including liver cancer and prostate cancer. This drug is currently in Phase II clinical trials in both China and the United States for treating recurrent and refractory liver cancer. Other pipeline products include AST-001 for pancreatic and bile duct cancer, and drugs targeting breast, ovarian, esophageal, and stomach cancers, which are in various stages of clinical and preclinical development. The company has secured significant venture capital backing through multiple funding rounds to advance its clinical programs and research.